PROGRAM OVERVIEW
This case-based enduring activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Describe the MOAs and clinical profiles of available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of RCC
- Recognize and manage side effects and toxicities associated with available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of RCC
- Review established prognostic and potential predictive immune- and non-immune-related biomarkers for RCC
- Discuss current recommendations and emerging evidence regarding the use of immunotherapies for patients with RCC during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine
- Explain patient-centered SDM approaches aimed at optimizing cancer care and survivorship for those with RCC and the role of emergency care physicians as part of multidisciplinary teams in the diagnosis and management of irAEs associated with immunotherapies used alone or in combination
ACCREDITATION AND DESIGNATION STATEMENTS
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.
Credits: 1.0 ANCC Contact Hour
Accreditation Statement
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
ONCC Statement
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1.0 knowledge-based contact hour for pharmacists/technicians. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
PROGRAM CHAIR & FACULTY PRESENTER
Arjun V. Balar, MD
Associate Professor of Medicine
Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, NY
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Balar reports the following disclosures:
Consulting fees/Advisory role: Genentech, Incyte, Janssen, Merck, Pfizer, AstraZeneca/Medimmune, Nektar, Seattle Genetics, and Immunomedics; Contracted research: Genentech, Nektar; Contracted research (institution): Genentech, Merck, AstraZeneca/Medimmune, Seattle Genetics, and Immunomedics; Speaking engagements: Genentech, Merck, and AstraZeneca/Medimmune; Steering/Scientific Advisory Committee: Merck; Steering Committee Membership: Nektar; Equity: EpiVax Oncology; Scientific Advisory Board Member: EpiVax Oncology.
Staff, Planners and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Brianna Hanson, MPH, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.
Debra Gordon, MS, Medical Director for Med Learning Group has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for the enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: August 20, 2021
EXPIRATION DATE: August 20, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
ENDURING ACTIVITY LEARNER NOTIFICATION
Med Learning Group
IC-ONC – Combination Treatment Options, Biomarkers and Immune-related Adverse Event Occurrence and Management During the COVID-19 Pandemic, Track 3: Advanced Renal Cell Carcinoma
August 20, 2021 – August 20, 2022
Online
Acknowledgement of Financial Commercial Support
Bristol Myers Squibb
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-158-H04-P / JA4008163-9999-21-158-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
Objectives – After Attending This Program You Should Be Able To
- Describe the MOAs and clinical profiles of available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of RCC.
- Recognize and manage side effects and toxicities associated with available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of RCC.
- Review established prognostic and potential predictive immune- and non-immune-related biomarkers for RCC.
- Discuss current recommendations and emerging evidence regarding the use of immunotherapies for patients with RCC during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine.
- Explain patient-centered SDM approaches aimed at optimizing cancer care and survivorship for those with RCC and the role of emergency care physicians as part of multidisciplinary teams in the diagnosis and management of irAEs associated with immunotherapies used alone or in combination.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5).
All individuals in a position to control the content of CE are listed below:
| Name | Relationship: Commercial Interest |
|---|---|
| Arjun V. Balar | Consultant: Genentech, Incyte, Janssen, Merck, Pfizer, AstraZeneca/Medimmune, Nektar, Seattle Genetics, Immunomedics; Contracted Research: Genentech, Nektar; Contracted Research (Institution): Genentech, Merck, AstraZeneca/Medimmune, Seattle Genetics, Immunomedics; Advisory/Steering Committee: EpiVax Oncology, Merck, Nektar; Equity: EpiVax Oncology |
| Matthew Frese | NA |
| Christina Gallo | NA |
| Debra Gordon | NA |
| Brianna Hanson | NA |
| Scott McGee-Plys | NA |
| Jessica McMullen | NA |
| Lauren Welch | NA |
How to Get Your Certificate
- Go to http://mlg.cmecertificateonline.com
- Click on “IC-ONC Enduring – Track 3: Advanced Renal Cell Carcinoma” link.
- Evaluate the meeting, click the provided link to open your credit certificate.
- Print/save all pages of your certificate for your records.
Questions?
Email [email protected]
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
